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Context: Self-limited delayed puberty (DP) is often associated with a delay in physical maturation,
but although highly heritable the causal genetic factors remain elusive. Genome-wide association
studies of the timing of puberty have identified multiple loci for age at menarche in females and
voice break in males, particularly in pathways controlling energy balance.
Objective/Main Outcome Measures: We sought to assess the contribution of rare variants in such
genes to the phenotype of familial DP.
Design/Patients:We performed whole-exome sequencing in 67 pedigrees (125 individuals with DP
and 35unaffected controls) fromour unique cohort of familial self-limitedDP. Using awhole-exome
sequencing filtering pipeline one candidate gene [fat mass and obesity–associated gene (FTO)]
was identified. In silico, in vitro, and mouse model studies were performed to investigate the
pathogenicity of FTO variants and timing of puberty in FTO+/2 mice.
Results:We identified potentially pathogenic, rare variants in genes in linkage disequilibrium with
genome-wide association studies of age at menarche loci in 283 genes. Of these, five genes were
implicated in the control of bodymass. After filtering for segregationwith trait, one candidate, FTO,
was retained. Two FTO variants, found in 14 affected individuals from three families, were also
associated with leanness in these patients with DP. One variant (p.Leu44Val) demonstrated altered
demethylation activity of the mutant protein in vitro. Fto+/2mice displayed a significantly delayed
timing of pubertal onset (P , 0.05).
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Conclusions: Mutations in genes implicated in body mass and timing of puberty in the general
population may contribute to the pathogenesis of self-limited DP. (J Clin Endocrinol Metab 103:
649–659, 2018)
Puberty is the maturational process of the reproductiveendocrine system that results in adult height and body
proportion, in addition to the capacity to reproduce. A
minimum level of energy availability is required for the
onset of puberty, whereas increased fat mass has been
shown to be associated with precocious onset of puberty
(1, 2). However, a role for genes connected with regu-
lation of body mass have not been clearly demonstrated
in pubertal timing.
The existence of genetic heterogeneity in pubertal
timing is supported by several large genome-wide asso-
ciation studies (GWAS) of the age at menarche (AAM)
(3–5). Evidence (P , 5 3 1028) for 123 signals at 106
genomic loci has been identified. Many of these loci
were associated with Tanner staging in both sexes,
suggesting that these data are applicable to both men and
women (6, 7).
The first of many GWAS loci associated with AAM
was the developmental gene LIN28B (3, 8). Additional
signals in genes involved in energy homeostasis and
growth have been found near LEPR-LEPROT, which
encodes the leptin receptor. Leptin (a key regulator of
bodymass) is an important permissive signal for the onset
of puberty (9). In addition to leptin signaling, overlap
with several genes implicated in body mass index was
found, including fat mass and obesity–associated gene
(FTO), SEC16B, TMEM18, and NEGR1 (Supplemen-
tal Table 1) (5). Whether such genes may regulate pu-
bertal timing exclusively via impact on fat mass or via
other body mass index (BMI)–independent mechanisms
is unknown (10).
Disordered pubertal timing affects up to 5% of ado-
lescents and is associated with adverse health and psy-
chosocial outcomes (11–14). Self-limited delayed puberty
(DP) represents the extreme end of normal pubertal
timing and is defined as the absence of testicular en-
largement in boys or breast development in girls at an age
that is 2 to 2.5 standard deviations (SD) later than the
populationmean (3). DPmay be an isolated feature of the
condition or be associated with constitutional delay in
growth that can manifest from early childhood.
DP segregateswithin families, usuallywith an autosomal-
dominant pattern of inheritance (15, 16). Despite strong
heritability in most cases the genetic basis of DP remains
elusive (17, 18). Moreover, the relevance of genetic factors
influencing timing of puberty in the general population to
patientswith extremepubertal delay has not been explored.
Given the importance of energy balance for reproductive
health, genes identified by AAM GWAS that relate
to energy homeostasis are of particular interest. Our
multigenerational DP families provide a highly valu-
able resource to investigate these candidate genes in
familial DP.
Materials and Methods
Patients
The patients selected for this study were taken from a pre-
viously described, accurately phenotyped and characterized,
Finnish DP patient cohort (19). Diagnosis is based on objective
evidence of a delayed pubertal growth spurt rather than self-
recall. Patients referred with DP to specialist pediatric care in
central and southern Finland (1982 to 2004) were identified. All
patients (n = 492) met the diagnostic criteria for self-limited DP,
defined as the onset of Tanner genital stage II (testicular vol-
ume . 3 mL) . 13.5 years in boys or Tanner breast stage II .
13.0 years in girls (i.e., 2 SD later than average pubertal de-
velopment) (18, 20). Pubertal growth spurt in probands was.2
SD later than average age at acceleration of pubertal growth
(take-off) beyond 13.8 and 12.2 years and age at peak height
velocity (PHV) later than 15.6 and 13.7 years in males and
females, respectively (21).
Chronic illness and undernutrition was excluded by med-
ical history, clinical examination, and routine laboratory tests.
Hypogonadotropic hypogonadism, if suspected, was excluded
by spontaneous pubertal development at follow-up. In the
50% of patients who choose to have pubertal induction via the
use of exogenous sex steroids, all patients were followed up
until the point of full pubertal development (Tanner stage G4+
or B4+) to ensure that development did not arrest when off
treatment.
Families of the patients with DP were invited to participate,
with information about medical history and pubertal timing
obtained by structured interviews and from archived height
records. The criteria for DP in probands’ family members were
one or more of: (1) age at takeoff; (2) PHV occurring 1.5 SD
beyond the mean, that is, age at takeoff exceeding 12.9 and
11.3 years, or age at PHV exceeding 14.8 and 12.8 years in
males and females; or (3) age at attaining adult height more than
18 or 16 years in males and females, respectively (19). Previous
linkage analysis from this cohort did not find evidence for linked
families sharing chromosomal segments identical by descent,
suggesting that a founder effect is unlikely to be responsible for
this phenotype (19).
Written informed consent was obtained from all partici-
pants. The study protocol was approved by the Ethics Com-
mittee for Pediatrics, Adolescent Medicine and Psychiatry,
Hospital District of Helsinki and Uusimaa (extended to en-
compass Kuopio, Tampere, and Turku University Hospitals)
(570/E7/2003). United Kingdom ethical approval was granted
by the London-Chelsea NRES Committee (13/LO/0257). The
study was conducted in accordance with the guidelines of the
Declaration of Helsinki.
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Genetic analysis
Genetic analysis was performed in 160 individuals from the
67 most extensive families from our cohort with DP. These
included 67 probands (male, n = 57; female, n = 10), 58 affected
family members (male, n = 36; female, n = 22), and 35 un-
affected family members (male, n = 13; female, n = 22). Whole-
exome sequencing (WES) was performed on DNA extracted
from peripheral blood leukocytes. Variants were analyzed
and filtered for potential causal variants in Ingenuity Variant
Analysis (Qiagen) using filters for quality control, predicted
functional annotation, minor allele frequency (MAF), and
GWAS relevance (Fig. 1). GWAS relevance filtering allowed
identification of those remaining variants that lay within genes
in linkage disequilibrium with 106 GWAS loci associated with
AAM (n = 760) (5). Filters for genes implicated in body mass
regulation were applied using a biological context filter with
pathway analysis. Variants were filtered for segregation with
trait in family members using conventional Sanger sequencing.
Targeted exome sequencing using a Fluidigm array of the
remaining candidate gene identified postfiltering was then
performed in a further 42 cohort families (288 individuals, 178
with DP [male, n = 106; female, n = 69) and 110 controls (male,
n = 55; female, n = 58); Fig. 1]. Whole-gene rare variant burden
testing was performed after sequencing.
Growth pattern analysis
The pattern of prepubertal growth in the individuals carrying
FTO variants was analyzed by using five screening parameters:
(1) height for age SD score (HSDS); (2) BMI (calculated as
weight in kilograms divided by height in meters squared) for age
SDS (BMI SDS); (3) HSDS distance from target height (target
height formula = 0.7913mean parental HSDS2 0.147 for girls
and 0.8863mean parental HSDS2 0.071 for boys; (4) change
in HSDS; and (5) change in BMI SDS across time with free age
intervals. The calculations of the age-specific and sex-specific
normal values for change in HSDS and change in BMI SDSwere
based on longitudinal reference measurements (22). Normality
of linear growth was tested by using auxological screening rules
based on data from .70,000 healthy Finnish children (23).
In silico analysis
The FTO experimentally solved structure (PDB identifier:
4cxx) was used to study the structural effect of FTO variants.
The following interactions involved in protein stability were
considered: (1) salt bridges; (2) hydrogen bonds (H-bond); and
(3) disulfide bridge (S–S bridge). N-glycosylation sites were
determined based on the consensus sequence Asn-X-Thr/Ser
(where X indicates any amino acid, except proline). The DSSP
program was used to calculate surface accessibility and Dis-
opred3 (24) was used to predict disordered protein regions.
Functional annotation of FTO mutant proteins
Cloning of wild-type (WT) human FTO cDNA into pET302/
NT-His has been described previously (25). The p.Leu44Val
and p.Ala163Thr point mutations were introduced using PCR-
mediated mutagenesis (QuickChange II, Agilent Technologies)
Figure 1. Flowchart of WES filtering strategy to identify candidate genes. WES was initially performed on DNA extracted from peripheral blood
leukocytes of 160 individuals from the 67 most extensive families from our cohort (125 with DP and 35 controls), with exome capture on
a Nimblegen v2 or Agilent v5 platform and sequencing on the Illumina HiSeq 2000. The exome sequences were aligned to the University of
California, Santa Cruz hg19 reference genome. Picard tools and the genome analysis toolkit were used to mark PCR duplicates, realign around
indels, and recalibrate quality scores and call variants. Variants were then analyzed further and filtered for potential causal variants using filters for
quality control, predicted functional annotation, minor allele frequency (MAF), segregation with trait, and GWAS relevance (see Materials and
Methods for further information on filtering criteria). Targeted exome sequencing using a Fluidigm array of a candidate gene identified after
filtering was then performed in a further 42 families from the same cohort (288 individuals, 178 with DP and 110 controls). Variants after
targeted resequencing were filtered using the same criteria as the WES data. Functional annotation of the variants is as described elsewhere in
Materials and Methods.
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using primers FTO_L44V (forward, 50-GAATTCTATCAG-
CAGTGGCAGGTGAAATATCCTAAACTAATTCT-30, reverse,
50-AGAATTAGTTTAGGATATTTCACCTGCCACTGCTGAT-
AGAATTC-30) and FTO_A163T (forward, 50-CACAGCATC-
CTCATTAGTCTTCTCTTTGGCAGCAA-30, reverse, 50-TTGC-
TGCCAAAGAGAAGACTAATGAGGATGCTGTG-30) and
verified by sequencing. An RNase-cleavage assay (26) was
used to measure the demethylation activity of FTO on 3-
methyl-uridine (3-meU). Recombinant WT and mutant FTO
expression plasmids were transformed into Escherichia coli
BL21-Gold (DE3) (Stratagene) and cultured in Luria-Bertani
broth and 50 mg/mL carbenicillin. Expression of the cloned
gene was induced by the addition of isopropyl-b-D-1-
thiogalactopyranoside at 1 mM final concentration at 15°C
for 4 hours. The cells were harvested and pellets resuspended
in lysis buffer [50 mM HEPES-KOH (pH 8.0), 2 mM 2-
mercaptoethanol, 5% glycerol, and 300mM NaCl] before
digestion with lysozyme (1 mg/mL). The cleared lysate was
supplemented with imidazole (final concentration 10 mM)
before mixing with 1 mL of prewashed nickel-nitrilotriacetic
acid beads (Qiagen). After binding for 1 hour in the cold, the
mixture was washed with lysis buffer supplemented with in-
creasing concentrations of imidazole. FTO was eluted with 2 ml
of lysis buffer containing 250 mM imidazole. The eluate was
concentrated with a 30 kDa molecular mass cut-off concen-
trator (Sartorius Stedim) with buffer changing to 20 mM
HEPES-KOH (pH 8), 5% glycerol, and 50 mM NaCl. Purified
proteins were snap-frozen and stored at 280°C. Protein purity
was estimated by Coomassie blue staining after resolving by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(4%–12% gradient gels; Invitrogen).
For the dose response of FTO on 3-meU demethylation,
recombinant FTO proteins were assayed as previously described
(26). Each protein, at different protein concentrations from 0 to
1000 nM,was assayed in a reaction containing 100 nM substrate,
75mMFe(NH4)2(SO)2, 300mM2-oxoglutarate, 2mMascorbate,
50 mg/mL bovine serum albumin, and 62.5 mg/mL RNase A in
50 mM Tris-HCl buffer at pH 7.0. Samples were prepared
in duplicate in a dark flat-bottomed 96-well plate and the 6-
carboxyfluorescein emission was measured for 30 minutes at a
wavelength of 520 nm with excitation at 485 nm. The mea-
surement was performed at room temperature (25°C) using a
microplate reader (Infinite M1000, Tecan). WT FTO protein and
catalytically inactive mutant p.Arg316Gln (R316Q) served as
positive and negative controls, respectively.
Mouse experiments
Fto-deficient mice were a gift from Prof. Roger Cox (Medical
Research Council Harwell, Oxford, U.K.) and were genotyped
as previously described (27). This research is regulated under the
Animals (Scientific Procedures) Act 1986 Amendment Regu-
lations 2012 following ethical review by the University of
Cambridge Animal Welfare and Ethical Review Body. Animals
were kept under controlled temperature (22°C) and a 12-hour
light/12-hour dark schedule (lights on 07:00 AM to 7:00 PM).
Standard chow (Special Diet Services) and water were available
ad libitum.
For the vaginal opening (VO) study, female Fto heterozygous
mice (Fto+/2) (n = 45) and their WT littermates (n = 24) were
taken from either amale FtoWT3 female Fto+/2 cross or amale
Fto+/2 3 female Fto WT cross. From postnatal day 21 (day of
weaning) all female mice were weighed and visual examination
of the vagina was carried out by placing the mouse on top of a
cage lid and lifting the tail vertically away from the body. No
excessive force was involved. The first day of VO was recorded
when a complete opening was observed.
For all experiments, data are expressed as the mean 6
standard error of the mean (SEM). To determine statistical
significance, we used the unpaired t test (two-tailed) using SPSS
software (version 24). A P value , 0.05 was considered sta-
tistically significant.
Results
Variants in GWAS genes implicated in body mass
were identified following exome sequencing in
families with self-limited DP
WES performed in the 67 largest and best phenotyped
families from our cohort [160 individuals: a total of 125
individuals with DP (male, n = 93; female, n = 32) and 35
controls (male, n = 13; female, n = 22)] identified
6,952,773 variants after quality control (Fig. 1). Filtering
to identify high-quality, rare, predicted deleterious var-
iants not present in control subjects selected 12,371
variants in 7,470 genes. Of these 7470 genes, 238 were
found to be in linkage disequilibrium with a GWAS locus
for timing of puberty, and 5 of these 238 were genes
implicated in body mass regulation or growth by path-
way analysis. Of these five genes, four (GPD2, GHR,
ESR1, and VDR) were found to have only variants that
did not segregate with the DP trait in family members.
The remaining candidate gene,FTO (ENSG00000140718,
gene identification number 79068), has been previously
described in the literature as involved in pathways of en-
ergy homeostasis and growth (5), and it is known to act
as an Fe(II) 2-oxoglutarate–dependent dioxygenase to re-
pair alkylated DNA and RNA by demethylation (26). FTO
contributes to the regulation of energy balance, and thus to
the regulation of body size and fat accumulation.
Two variants in FTO [NM_001080432.2: c.130C.
G p.Leu44Val and NM_001080432.2: c.487G.A
(rs145884431) p.Ala163Thr] were identified in three
families from our cohort and found in one or fewer
control subjects (rare variant burden testing adjusted P =
0.058). Both variants are rare (MAF , 0.2%) hetero-
zygous missense variants and are predicted to be benign
or tolerated by more than two of five prediction
software tools.
Families with potentially pathogenic FTO variants
display autosomal-dominant inheritance of DP
phenotype and low body mass
The family identified with the p.Ala163Thr variant
(family 1) and both of the families with the p.Leu44Val
variant (families 2 and 3) displayed the typical autoso-
mal inheritance pattern of the DP trait, with perfect
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Figure 2. Pedigrees and auxological data of the families with potentially pathogenic FTO variants. (a) Squares indicate male family members; circles
indicate female family members. Black symbols represent clinically affected, gray represent unknown phenotype, and clear symbols represent unaffected
individuals. The arrowhead with “P” indicates the proband in each family, and “us” indicates unsequenced due to lack of DNA from that individual. The
mutation in each family is given next to the family number; a horizontal black line above an individual’s symbol indicates that they are heterozygous for
the variant as confirmed by either WES or Fluidigm array, and verified by Sanger sequencing. A red dot indicates that the individual was
underweight (thinness grade 2 or more significant) and ‘?’ indicates that BMI information for that individual is not available. (b–d) BMI and
HSDS charts for the probands of each of the three pedigrees (family 1.III.2, family 2.III.5, and family 3.III.2). Underweight values are shown in
red, green dots indicate a significant deflection from previous height measurements, and orange dots indicate significant deflection from
target height. Normal values, based on data from .70,000 healthy Finnish children, have been previously published (22).
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segregation [Fig. 2(a)]. Affected individuals from family 1
with the p.Ala163Thr variant and from family 3 with the
p.Leu44Val variant were particularly underweight in
childhood, with the two probands from these families
(individuals 1.III.2 and3.III.2) falling into the thinness grade
2 category (28) before puberty [Fig. 2(b) and 2(d)]. Al-
though there was some variability in this phenotype, all
family members carrying FTO variants had age- and sex-
adjusted BMI values in the lower range
(,23) (Fig. 2; Supplemental Figs. 1–3;
Table 1). Additionally, both of the
probands from families 2 and 3 who
carry the p.Leu44Val displayed faltering
growth in early childhood. Both dis-
played significant deflection from pre-
vious heightmeasurements in the 2 years
following birth, as well as height sig-
nificantly below target height in later
adolescence associated with delayed
pubertal growth [Fig. 2(c) and 2(d)] (22).
In silico analysis of
potential mutations
We carried out in silico analysis us-
ing the solved structure of FTO (PDB
identifier: 3lfm) to determine the pos-
sible pathogenicity of the identified
variants. The hydrophobic residue leu-
cine 44 is part of a solvent-exposed a
helix on the surface. Substitution with
valine is notpredicted toalter the structure
of FTOor interactionwith ironmolecules
or DNA. However, L44 and other resi-
dues in the same solvent-exposed a helix
formamotif (Supplemental Figs. 4 and5),
which is highly conserved across placental
mammals but not reptiles, birds, or fish
(Supplemental Fig. 6). This motif (resi-
dues 36 to 48) forms a patch on the FTO
protein surface (Supplemental Fig. 7).This
Table 1. Clinical Data of Probands With FTO Variants
Case Sex
Amino Acid
Alteration
HSDS at
Age 4 Years
HSDS at
Age 8/9 Years
HSDS at
Age 18 Years
Age- and Sex-Adjusted
BMI at Age 18 Years
1.II.1 M p.Ala163Thr — 1.1 1.7 16.9
1.III.2 (P) M p.Ala163Thr 1.1 0.5 1.1 17.1
1.III.1 F p.Ala163Thr 0.9 1.0 1.1 17.3
1.II.5 M p.Ala163Thr 21.0 21.0 20.4 —
2.III.5 (P) M p.Leu44Val 20.9 21.4 21.5 18.8
2.III.6 M p.Leu44Val 21.1 21.3 — —
2.II.2 M p.Leu44Val — 20.8 20.8 20.5
2.III.1 M p.Leu44Val 0 21.4 — —
3.II.2 M p.Leu44Val — 21.0 20.9 18.6
3.III.2 (P) M p.Leu44Val 20.9 21.1 21.3 18.7
3.II.3 M p.Leu44Val 20.4 20.1 22.7
3.III.3 M p.Leu44Val 20.1 0.2 0.5 17.8
Height is expressed as SDS for national reference data for Finland at 4 years of age and at either 8 years for girls or 9 years for boys. Normal limits: change in
HSDS ,1.21, distance to target height at 4 years ,1.76, distance to target height at 8/9 years ,1.72 (22). P, proband.
Figure 3. Demethylation assay assessing kinetic activity of mutant vs WT FTO proteins. FTO
activity is proportional to the concentration present in the reaction. Demethylase activity is
likely to be related to the ability of FTO to function as a sensor for cellular metabolism (29).
The R316Q mutant is enzymatically dead across all concentrations tested. The A163T and
L44V mutants showed demethylase activity toward methylated uridine in a dose-dependent
manner but with different affinities.
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may act as a mammal-specific interaction site (between FTO
and another protein) required for FTO function, for exam-
ple, in reproductive development. In this scenario, a small
change in side chain volume, such as leucine-to-valine, may
havea subtle effect inprotein–protein interactionand lead toa
change in FTO activity in vivo.
Alanine 163 is a hydrophobic, not highly conserved
residue (Supplemental Fig. 8A). Alanine 163 is at the
end of the H4 a helix and the beginning of a long, dis-
ordered region (Supplemental Fig. 8B), which connects
helices H4 and H5 (Supplemental Fig. 8C).
FTO p.Leu44Val mutant protein displays reduced
demethylase activity in vitro
We carried out functional characterization of the iden-
tified mutant FTO proteins (p.Leu44Val and p.Ala163Thr)
as comparedwithWTprotein.Apreviously verifiedRNase-
cleavage assay was used to measure the demethylation
activity of FTO on 3-meU (26). Although kinetic activity of
the mutant protein p.Ala163Thr did not vary from WT
using this assay, mutant protein p.Leu44Val showed an
;20% lower kinetic activity thanWT activity (Fig. 3) (29).
FTO deficiency in vivo results in delayed VO in mice
To examine the influence of FTO activity on pubertal
timing in an in vivo model, we examined timing of
puberty in mice deficient for FTO in the heterozygous
state (Fto+/2), in keeping with the human genotype
identified. Fto2/2 mice were not selected for these ex-
periments because of their poor postnatal health (30).
Fto+/2mice had significantly delayed timing of VO [mean
postnatal day 6 SEM: 27.20 6 0.44 in WT (n = 24) vs
28.56 6 0.48 in Fto+/ mice (n = 45), P = 0.047], an event
that reflects the pubertal rise in estradiol (31) (Fig. 4).
Mean body weight of the Fto+/ group was not signifi-
cantly different from the WTmice [mean body weight (in
grams) 6 SEM: 11.64 6 0.21 in WT vs 11.45 6 0.14 in
Fto+/ mice, P = 0.467] (Fig. 5).
Using simple linear modeling, the Fto genotype of the
pup (heterozygous vs WT) explained ;3% of the total
variation in timing of VO. Consideration of an additional
factor, maternal genotype, improved the model by in-
creasing the significance of the association between pup
genotype and timing of VO slightly (P = 0.04), and
accounted for 6% of the total variation in timing of VO.
In contrast, paternal genotype decreased the significance
and total variation accounted for by the model.
Discussion
GWAS of AAM in the general population have attempted
to unravel the complex conundrum of which genetic
factors influence the timing of puberty.
Despite many loci being identified,
clear evidence for the role of particular
genes and pathways is for the most part
lacking. Those genes lying within path-
ways of energy metabolism and growth
appear promising, with the discovery of
the role of Lin28B in Caenorhabditis
elegans development (3) and the im-
portance of leptin as a permissive signal
in triggering the onset of puberty (9, 32).
The inheritance of DP is known to
be under strong genetic influence with
commonly an autosomal-dominant in-
heritance pattern, and thus represents
a useful basis for the investigation of
puberty genetics. Notably, self-limited
or constitutional DP is often associated
with slow maturation throughout child-
hood, implicating growth and energy
metabolism pathways in its pathogene-
sis. Previously, genes in such pathways
identified through GWAS have not been
screened in patients with DP.
Our results have identified vari-
ants in FTO as a potential contributory
factor in the development of self-limited
Figure 4. Timing of VO in WT and FTO+/2heterozygous mice. Cumulative percentages of
mice displaying VO by postnatal day are shown for WT and FTO+/2 mice. WT mice, n = 24;
FTO+/2 mice, n = 45. P , 0.05 by unpaired t test. het, heterozygous.
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DP in three pedigrees from our large cohort of patients
with familial DP. FTOwas the first obesity-susceptibility
gene identified through GWAS and continues to be the
locus with the largest effect on BMI and obesity risk (10).
Those DP patients identified with FTO variants from our
study showed reductions in bodymass. The FTO variants
carried by our DP patients may result in reduced fat mass,
which would in turn contribute to a delay in the timing of
pubertal onset. This delay may be mediated directly
through reduced leptin levels. Although we do not rou-
tinely measure leptin levels in DP patients, leptin levels
have been shown to be significantly lower in pubertal-age
patients with self-limited DP (33).
Notably, in an in vivo model, Fto+/2 mice had a sig-
nificantly delayed onset of puberty as compared withWT
mice. In the 7 days preceding puberty onset, however,
body weight was not significantly different between the
two pup genotype groups. Previous studies have dem-
onstrated that Fto2/2 mice show a 30% to 40% re-
duction in body weight by 6 weeks of age (30) and that
transgenic mice with additional copies of Fto show a
dose-dependent increase in body and fat mass (34).
However, the relationship between FTO genotype, fat
mass, and leptin levels remains some-
what unclear. Fto-deficient mice do
become obese when subjected to a
high-fat diet, although they remain
sensitive to the anorexigenic effects
of leptin (30, 35).
Moreover, it is possible that FTO
gene dosage may have an effect on
energy homeostasis independent of
effects on fat mass (34), including on
the balance between catabolic and
anabolic pathways (36). FTO has been
identified as an amino acid sensor
acting, via mTOR, to influence ap-
propriate levels of development and
translation (29). FTO is expressed
within the hypothalamus in several sites
critical for energy balance, including in
the arcuate nucleus within proopiome-
lanocortin neurons (37, 38). In one
study Fto levels in the arcuate nuclei of
fasted mice fell by up to 60%, and
this was not rescued by leptin adminis-
tration. Other studies have shown
conflicting results in the effects on
Fto messenger RNA levels of fasting,
depending on whether whole hypo-
thalamus or arcuate nucleuswas studied
and on the length of fast (38). However,
Fto2/2 mice display blunted starvation-
induced Npy messenger RNA induction (30). More recent
studies have suggested that Ftomay influence themetabolic
outcomes of a high-fat diet via hypothalamic signaling
pathways acting independently of body weight (35).
Mutations in FTO, including those with greatly reduced
demethylase activity (e.g., pR316Q, Fig. 3), have been
identified in human subjects associated with both lean and
obese phenotypes (25). We were not able in our study to
identify the mechanism by which the p.Ala163Thr variant
might affect protein function; although no reduction in
demethylation activity was demonstrated, it is possible that
this variant may produce a deleterious effect by another
route, for example by defects in posttranslational modifi-
cation or protein degradation.
Thus, FTO may be important for signaling energy
sufficiency and the “healthy energy balance” required
for pubertal onset. Our in silico analysis suggests that the
p.Leu44Val mutation we have identified may represent a
mammal-specific interaction site between FTO and another
protein (or DNA), important for FTO function in terms of
reproductive development. Moreover, maternal genotype
may contribute to pubertal timing, as demonstrated from
our Fto+/2 mice data. A reproductive phenotype present in
Figure 5. Mean body weight (grams) for WT and Fto+/2 (heterozygous) mice in 7 days prior
to VO. Mean body weight (grams) 6 SEM: 11.64 6 0.21 in WT mice (n = 24) vs 11.45 6
0.14 in Fto+/ mice (n = 45). P = 0.467 by unpaired t test. Error bars show SEM for each
group each day. HET, heterozygous.
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Ftoheterozygotemothers could exposepups to a suboptimal
environment that could influence their puberty timing.
Finally, our finding of maturational delay in growth in
early childhood in the two probands with p.Leu44Val
mutation is of interest. Constitutional delay in growth is
seen in a subset of patients with DP, and our findings
implicate mutations in energy pathway genes in the
pathogenesis of patients with such a phenotype.
Overall, our discovery of two rare variants in FTO
associatedwith self-limitedDP in our large familial cohort,
and of delayed VO in FTO-deficient mice, provides evi-
dence that perturbations in pathways of energy homeo-
stasis and growth may potentially produce a phenotype of
DP. We note that despite this extensive analysis, only 3 of
67 probands were identified with potentially pathogenic
variants in such pathways, highlighting the high degree of
heterogeneity in the genetic basis of self-limited DP. These
findings merit further exploration in our own cohort and
in other populations, including subgroup analysis of DP
patients with low BMI from early childhood.
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